Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat

Dow Jones

03/10

By Elias Schisgall

Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year.

Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year.

The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier.

Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000.

Analysts were expecting a loss of $2.35 a share and $2 million in revenue.

The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness.

It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 09, 2026 13:51 ET (17:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2618675097"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618675097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618675097?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618675097","market":"sg","top_or_hot":-1,"title":"Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n</p>\n<p>\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n</p>\n<p>\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n</p>\n<p>\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n</p>\n<p>\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n</p>\n<p>\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n</p>\n<p>\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Stock Gains on Full-Year Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-10 01:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n</p>\n<p>\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n</p>\n<p>\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n</p>\n<p>\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n</p>\n<p>\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n</p>\n<p>\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n</p>\n<p>\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAC","symbol_name":"Cartesian Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618675097","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618675097","pubTimestamp":1773078660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year.Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year.The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier.Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000.Analysts were expecting a loss of $2.35 a share and $2 million in revenue.The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness.It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation,","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RNAC":"Cartesian Therapeutics"},"translate_title":"Cartesian Therapeutics股价因全年收入超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n\n\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n\n\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n\n\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n\n\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n\n\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n\n\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 13:51 ET (17:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}